Talphera, Inc. (TLPH)
USD 0.49
(-13.84%)
USD 0.49
(-13.84%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 20.39 Million USD | -57.05% |
| 2022 | 47.48 Million USD | -39.04% |
| 2021 | 77.89 Million USD | 17.49% |
| 2020 | 66.29 Million USD | -27.43% |
| 2019 | 91.35 Million USD | -24.21% |
| 2018 | 120.53 Million USD | 59.54% |
| 2017 | 75.55 Million USD | -24.44% |
| 2016 | 99.99 Million USD | -21.75% |
| 2015 | 127.78 Million USD | 47.87% |
| 2014 | 86.41 Million USD | -21.46% |
| 2013 | 110.03 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 24.85 Million USD | -13.61% |
| 2024 Q1 | 28.77 Million USD | 41.07% |
| 2023 FY | 20.39 Million USD | -57.05% |
| 2023 Q3 | 23.26 Million USD | 31.23% |
| 2023 Q4 | 20.39 Million USD | -12.32% |
| 2023 Q1 | 26.29 Million USD | -44.63% |
| 2023 Q2 | 17.72 Million USD | -32.58% |
| 2022 Q2 | 56.13 Million USD | -22.01% |
| 2022 Q4 | 47.48 Million USD | -1.7% |
| 2022 FY | 47.48 Million USD | -39.04% |
| 2022 Q1 | 71.97 Million USD | -7.6% |
| 2022 Q3 | 48.31 Million USD | -13.94% |
| 2021 Q3 | 72.26 Million USD | -9.2% |
| 2021 Q4 | 77.89 Million USD | 7.79% |
| 2021 Q2 | 79.58 Million USD | -8.89% |
| 2021 Q1 | 87.34 Million USD | 31.76% |
| 2021 FY | 77.89 Million USD | 17.49% |
| 2020 Q4 | 66.29 Million USD | 0.18% |
| 2020 FY | 66.29 Million USD | -27.43% |
| 2020 Q1 | 77.33 Million USD | -15.34% |
| 2020 Q3 | 66.17 Million USD | -1.81% |
| 2020 Q2 | 67.4 Million USD | -12.85% |
| 2019 Q3 | 104.97 Million USD | -8.8% |
| 2019 Q2 | 115.11 Million USD | 1.47% |
| 2019 Q1 | 113.44 Million USD | -5.88% |
| 2019 FY | 91.35 Million USD | -24.21% |
| 2019 Q4 | 91.35 Million USD | -12.98% |
| 2018 Q4 | 120.53 Million USD | 55.04% |
| 2018 FY | 120.53 Million USD | 59.54% |
| 2018 Q3 | 77.74 Million USD | 20.31% |
| 2018 Q2 | 64.62 Million USD | -1.81% |
| 2018 Q1 | 65.81 Million USD | -12.89% |
| 2017 Q1 | 88.44 Million USD | -11.55% |
| 2017 Q3 | 82.74 Million USD | 5.82% |
| 2017 Q4 | 75.55 Million USD | -8.69% |
| 2017 Q2 | 78.19 Million USD | -11.59% |
| 2017 FY | 75.55 Million USD | -24.44% |
| 2016 Q2 | 113.57 Million USD | -6.31% |
| 2016 Q4 | 99.99 Million USD | -5.67% |
| 2016 Q3 | 105.99 Million USD | -6.67% |
| 2016 FY | 99.99 Million USD | -21.75% |
| 2016 Q1 | 121.22 Million USD | -5.13% |
| 2015 Q4 | 127.78 Million USD | -2.87% |
| 2015 Q2 | 63.56 Million USD | -15.92% |
| 2015 FY | 127.78 Million USD | 47.87% |
| 2015 Q3 | 131.56 Million USD | 106.99% |
| 2015 Q1 | 75.59 Million USD | -12.53% |
| 2014 FY | 86.41 Million USD | -21.46% |
| 2014 Q4 | 86.41 Million USD | -10.4% |
| 2014 Q1 | 100.41 Million USD | -8.74% |
| 2014 Q2 | 100.37 Million USD | -0.04% |
| 2014 Q3 | 96.44 Million USD | -3.92% |
| 2013 Q3 | 80.66 Million USD | 97.71% |
| 2013 Q1 | 52.98 Million USD | 0.0% |
| 2013 FY | 110.03 Million USD | 0.0% |
| 2013 Q4 | 110.03 Million USD | 36.41% |
| 2013 Q2 | 40.79 Million USD | -23.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | 97.745% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | 64.48% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | 98.216% |
| Cosmos Health Inc. | 66.29 Million USD | 69.236% |
| Dynavax Technologies Corporation | 997.09 Million USD | 97.955% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | 97.2% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | 98.705% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 25.421% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | 25.421% |
| SCYNEXIS, Inc. | 128.41 Million USD | 84.118% |
| Safety Shot Inc | 12.7 Million USD | -60.475% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | 11.813% |
| Alpha Teknova, Inc. | 128.58 Million USD | 84.139% |
| Bright Green Corporation | 17.4 Million USD | -17.192% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | 90.09% |
| Embecta Corp. | 1.21 Billion USD | 98.321% |
| PainReform Ltd. | 9.93 Million USD | -105.388% |
| Journey Medical Corporation | 76.84 Million USD | 73.461% |
| Procaps Group, S.A. | 460.18 Million USD | 95.568% |
| Theratechnologies Inc. | 77.76 Million USD | 73.775% |
| Harrow Health, Inc. | 311.75 Million USD | 93.458% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -36.944% |
| Biofrontera Inc. | 27.93 Million USD | 26.983% |
| DURECT Corporation | 45.18 Million USD | 54.867% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 98.552% |
| Cronos Group Inc. | 1.13 Billion USD | 98.202% |
| OptiNose, Inc. | 107.72 Million USD | 81.068% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | 95.671% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | 63.547% |
| RedHill Biopharma Ltd. | 23.04 Million USD | 11.507% |
| Organogenesis Holdings Inc. | 460.02 Million USD | 95.567% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -71.125% |
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | 75.06% |
| Radius Health, Inc. | 1.71 Billion USD | 98.811% |
| Universe Pharmaceuticals INC | 53.28 Million USD | 61.726% |
| ProPhase Labs, Inc. | 91.92 Million USD | 77.814% |
| Phibro Animal Health Corporation | 982.18 Million USD | 97.924% |
| Procaps Group S.A. | 460.18 Million USD | 95.568% |
| Alvotech | 950.09 Million USD | 97.853% |
| TherapeuticsMD, Inc. | 43.3 Million USD | 52.908% |
| Viatris Inc. | 47.68 Billion USD | 99.957% |
| Rockwell Medical, Inc. | 52.17 Million USD | 60.909% |
| Aytu BioPharma, Inc. | 118.09 Million USD | 82.73% |
| SIGA Technologies, Inc. | 254.83 Million USD | 91.997% |
| Tilray Brands, Inc. | 4.33 Billion USD | 99.53% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | 92.548% |
| Shineco, Inc. | 84.17 Million USD | 75.772% |
| PetIQ, Inc. | 868.22 Million USD | 97.651% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -141.698% |
| Incannex Healthcare Limited | 17.04 Million USD | -19.64% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 99.373% |
| Alimera Sciences, Inc. | 153.52 Million USD | 86.715% |
| Silver Spike Investment Corp. | 88.57 Million USD | 76.975% |
| Assertio Holdings, Inc. | 286.41 Million USD | 92.879% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -242.673% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | 39.652% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | 34.721% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -53.953% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | 92.19% |
| Hempacco Co., Inc. | 18.04 Million USD | -13.035% |
| Alvotech | 950.09 Million USD | 97.853% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | 94.979% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | 98.765% |
| Currenc Group, Inc. | 141.49 Million USD | 85.586% |
| Kamada Ltd. | 351.96 Million USD | 94.205% |
| Indivior PLC | 1.95 Billion USD | 98.955% |
| Evoke Pharma, Inc. | 7.06 Million USD | -188.532% |
| Flora Growth Corp. | 23.62 Million USD | 13.676% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -53.953% |
| Evolus, Inc. | 188.99 Million USD | 89.209% |
| HUTCHMED (China) Limited | 1.27 Billion USD | 98.406% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | 98.652% |
| Akanda Corp. | 8.83 Million USD | -130.713% |